CoChat
Sign Up
Cited by 1,196Pain Management and Placebo EffectGastrointestinal motility and disordersAcupuncture Treatment Research Studies

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

Open access
Kaptchuk, Ted J, Kelley, John M, Conboy, Lisa A, Davis, Roger B, Kerr, Catherine E, Jacobson, Eric E, Kirsch, Irving, Schyner, Rosa N, Nam, Bong Hyun, Nguyen, Long T, Park, Min, Rivers, Andrea L, McManus, Claire, Kokkotou, Efi, Drossman, Douglas A, Goldman, Peter, Lembo, Anthony J·2008·BMJ
DOI 10.1136/bmj.39524.439618.25PMC PMC2364862
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. DESIGN: A six week single blind three arm randomised controlled trial. SETTING: Academic medical centre. PARTICIPANTS: 262 adults (76% women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of > or =150 on the symptom severity scale. INTERVENTIONS: For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient-practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. MAIN OUTCOME MEASURES: Global improvement scale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life. RESULTS: At three weeks, scores on the global improvement scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for waiting list versus "limited" versus "augmented," respectively (P<0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28% on waiting list, 44% in limited group, and 62% in augmented group (P<0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P<0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P<0.001). All pairwise comparisons between augmented and limited patient-practitioner relationship were significant: global improvement scale (P<0.001), adequate relief of symptoms (P<0.001), symptom severity score (P=0.007), quality of life (P=0.01). Results were similar at six week follow-up. CONCLUSION: Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient-practitioner relationship is the most robust component. TRIAL REGISTRATION: Clinical Trials NCT00065403.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.39524.439618.25

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 3

  1. [7]7. PatelSM,StasonWB,LegedzaA,OckSM,KaptchukTJ,ConboyL,etal. The placebo effect irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332-40.
  2. [15]15. Chaput de Saintonge M, Herxheimer A. Harnessing the placebo effect in healthcare. Lancet 1994;344:995-8.
  3. [17]17. Drossman DA, Drossman D, Toner BB, Whitehead WE, Diamant NE, Dalton CB, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31.

Cited by

Sorted by citations

Items 601–700 of 999

Related

See all

Metadata

Authors
Kaptchuk, T. J., Kelley, J. M., Conboy, L. A., Davis, R. B., Kerr, C. E., Jacobson, E. E., Kirsch, I., Schyner, R. N., Nam, B. H., Nguyen, L. T., Park, M., Rivers, A. L., McManus, C., Kokkotou, E., Drossman, D. A., Goldman, P., & Lembo, A. J.
Affiliations
  • Harvard University (US)
  • Endicott College (US)
  • Beth Israel Deaconess Medical Center (US)
  • University of Hull (GB)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Kaptchuk, Ted J
ORCID
Venue
BMJ
Publisher
BMJ
Published
2008-04-03
Volume
336
Issue
7651
Pages
999-1003
ISSN
  • 1756-1833 (ISSN-L)
  • 0959-8138
DOI
10.1136/bmj.39524.439618.25
PMC
PMC2364862
OpenAlex
W2038810061
Cited by
1,196
References
35
Citations by year
2026: 32 · 2025: 48 · 2024: 49 · 2023: 53 · 2022: 56 · 2021: 78 · 2020: 70 · 2019: 78 · 2018: 75 · 2017: 80 · 2016: 72 · 2015: 66 · 2014: 77 · 2013: 76 · 2012: 60
FWCI
38.88
Type
journal article
Language
en
Open access
Licence
www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html (tdm)
Locations
  • BMJ (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Beth Israel Deaconess Medical Center
  • Harvard University
  • National Institutes of Health (5r21at002564-02)
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Complementary and Alternative Medicine
  • National Center for Research Resources (RR 01032, M01RR001032)
  • Office of Behavioral and Social Sciences Research
  • National Center for Complementary and Integrative Health (R01AT004662, R21AT002860, 1R21 AT002564, K24AT004095, R01AT001414)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
Keywords
placebo effect, irritable bowel syndrome, sham acupuncture, patient-practitioner relationship, healing rituals, non-specific effects, symptom severity, quality of life, symptom relief, placebo-controlled trial design
MeSH terms
Adult, Female, Humans, Male, Waiting Lists, Acupuncture Therapy, Placebo Effect, Single-Blind Method, Treatment Outcome, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review